ProMIS Neurosciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

WARRANTS

WARRANTS

12 Months Ended

Dec. 31, 2024

WARRANTS

WARRANTS

7.WARRANTS

As of December 31, 2024, outstanding Common Share warrants and exercise prices related to unit offerings are as follows:


Exercise	Number of
Price $	Warrants	Expiry date
C$12.00	279,613	November 2025
US$12.60	524,088	August 2026
US$9.60	146,744	August 2026
US$7.50	345,938	April 2028
US$6.10	69,188	April 2028
US$1.75	11,227,714	February 2029
US$2.02	14,128,696	January 2026
US$2.02	14,128,696	January 2027
US$2.50	14,128,696	July 2029
US$0.01	2,162,013	None
	57,141,386

During the years ended December 31, 2024 and 2023, 407,978 and 100,073 warrants expired without being exercised.

During the years ended December 31, 2024 and 2023, 2,803,738 and 360,000 pre-funded warrants were exercised for an equivalent number of common shares for net proceeds of $28,038 and $3,600, respectively.